Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Hans R. Hendriks"'
Autor:
Vincent Vuaroqueaux, Hans R. Hendriks, Hoor Al-Hasani, Anne-Lise Peille, Samayita Das, Heinz-Herbert Fiebig
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-11 (2021)
Abstract MI-773 is a recently developed small-molecule inhibitor of the mouse double minute 2 (MDM2) proto-oncogene. Preclinical data on the anti-tumour activity of MI-773 are limited and indicate that tumour cell lines (CLs) with mutated TP53 are mo
Externí odkaz:
https://doaj.org/article/fa935edd769044dbbcb37ff0f6b1cc5a
Autor:
Godefridus J. Peters, Anne-Sophie Govaerts, Hans R. Hendriks, for EORTC Pharmacology and Molecular Mechanism Group
Publikováno v:
ADMET and DMPK, Vol 6, Iss 1, Pp 4-14 (2018)
Drug development consists of many sequential and parallel steps; failure in one of the steps can lead to discontinuation of the process. The process is time-consuming and very expensive, especially the clinical phase. In order to enhance cancer drug
Externí odkaz:
https://doaj.org/article/20d0c7f90ac847cda41fa113cde4fb9d
Publikováno v:
Molecular Cancer Therapeutics. 18:C075-C075
4HF Biotec recently developed an in-silico platform dedicated to cancer data investigations. It connects cancer-related molecular and drug sensitivity information enabling target and biomarker discovery. We used the platform to perform an integrative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bce8a538923f24bb2c1a31a1e6d42815
https://doi.org/10.1158/1535-7163.targ-19-c075
https://doi.org/10.1158/1535-7163.targ-19-c075
Publikováno v:
Molecular Cancer Therapeutics. 18:C060-C060
The Mouse Double Minute 2 (MDM2) proto-oncogene is a primary cellular inhibitor of p53 tumor suppressor protein. MDM2 encodes for a nuclear-localized E3 ubiquitin-protein ligase via direct interaction responsible for proteasomal degradation of p53. I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae64c1f23aa82f2fb39c2da4f096c2b5
https://doi.org/10.1158/1535-7163.targ-19-c060
https://doi.org/10.1158/1535-7163.targ-19-c060
Publikováno v:
Cancer Research. 79:3074-3074
The BET family of bromodomain proteins (BRD2, BRD3, BRD4, and BRDT) has emerged as a promising new cancer target for small-molecule drug discovery. GSK 1324726A (I-BET726) is a highly selective inhibitor of BET family proteins that binds BRD2, BRD3 a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6933ed750263bed9525a3abcd0b5ef3
https://doi.org/10.1158/1538-7445.am2019-3074
https://doi.org/10.1158/1538-7445.am2019-3074
Publikováno v:
Cancer Research. 79:2196-2196
MEK inhibitors emerged as a promising class of anti-cancer agents to inhibit KRAS/RAF driven tumors like melanoma and colorectal cancer. GDC-0623 is a potent ATP-noncompetitive allosteric MEK1 inhibitor. The compound forms a strong hydrogen bond with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8fed6e914414033acb6cf8726bd2f0c
https://doi.org/10.1158/1538-7445.am2019-2196
https://doi.org/10.1158/1538-7445.am2019-2196
Publikováno v:
Molecular Cancer Therapeutics. 17:B167-B167
The p38 MAPK pathway, also called stress activated protein kinase pathway, is involved in basic cellular processes of inflammation and acts on cell growth, proliferation, differentiation, migration, and apoptosis. p38 MAP kinase activation occurs by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::385ca86657b8ba5fbae34069402bd542
https://doi.org/10.1158/1535-7163.targ-17-b167
https://doi.org/10.1158/1535-7163.targ-17-b167
Autor:
Andrew Tsotinis, Hans R. Hendriks, Vanessa Polychroniou, Maria Koufaki, Alexandros Makriyannis, Sophie LeClerc, Theodora Calogeropoulou, Heiner H. Fiebig, Markus Drees
Publikováno v:
Journal of Medicinal Chemistry 39:13(Jun1996):2609-2614
Two series of phosphodiester ether lipid analogs with (N-methylmorpholino)ethyl or (N-methylpiperidino)ethyl polar head groups and long aliphatic or alkoxyethyl chains in the nonpolar portion of the molecule were synthesized as potential antineoplast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b24e1800886be7a90f91678d42b0ab7c
http://helios-eie.ekt.gr/EIE/handle/10442/8015
http://helios-eie.ekt.gr/EIE/handle/10442/8015
Autor:
Pornima Phatak, Hans R Hendriks, Fangping Dai, Peter L. Gutierrez, M.P. Nandakumar, Angelika M. Burger, Martin J. Edelman, Melody Butler
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 14(14)
Purpose: KML001 (sodium metaarsenite) is an orally bioavailable arsenic compound that has entered phase I/II clinical trials in prostate cancer. In this study, we elucidated the mode of action of KML001 and investigated its effects on telomerase and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61d8ccec833109c8ddc59d9cf442bb97
https://pubmed.ncbi.nlm.nih.gov/18628474
https://pubmed.ncbi.nlm.nih.gov/18628474
Publikováno v:
Immunobiology. 180:295-307
The influence of recirculating lymphocytes on the function and morphology of high endothelial venules (HEV) has been studied. Mice were depleted of lymphocytes by lethal (1200 cGy) total body irradiation; subsequently, the HEV in mesenteric and cervi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0387a7ad779f9e8f3e33b1d4d3899ea
https://doi.org/10.1016/s0171-2985(11)80293-7
https://doi.org/10.1016/s0171-2985(11)80293-7